OVERVIEW

Individualizing the Management of Hematologic Malignancies: Genomics, Targeted Therapeutic Options, and Treatment Sequencing is organized by Med Learning Group.

Dates:
Release Date: Oct 02, 2019
Expiration Date: Oct 02, 2020

Accreditation:
Credit Designation Statement:
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Credit Information:
Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with AML.
CNE Credits: 1.0 ANCC Contact Hour(s)

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.

Description:
This enduring activity will cover the treatment and management of patients with acute myeloid leukemia (AML).

Objectives:
Upon completion of the activity, attendees should be able to:
• Assess the treatment implications of common mutations and abnormalities for patients with previously untreated and relapsed/refractory (R/R) AML;
• Describe current and novel therapeutic approaches for patients with previously untreated and R/R AML;
• Develop treatment plans individualized for each patient with previously untreated or R/R AML that integrate new agents and account for risks related to adverse events; and
• Discuss strategies that will improve communication, engagement, education, and decision making with patients with previously untreated and R/R AML and their healthcare providers.

Additional details will be posted as soon as information is available.